NO20052267L - Forbindelser, Preparater og Metoder - Google Patents
Forbindelser, Preparater og MetoderInfo
- Publication number
- NO20052267L NO20052267L NO20052267A NO20052267A NO20052267L NO 20052267 L NO20052267 L NO 20052267L NO 20052267 A NO20052267 A NO 20052267A NO 20052267 A NO20052267 A NO 20052267A NO 20052267 L NO20052267 L NO 20052267L
- Authority
- NO
- Norway
- Prior art keywords
- preparations
- compounds
- methods
- ksp
- triazol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- MDTUWBLTRPRXBX-UHFFFAOYSA-N 1,2,4-triazol-3-one Chemical class O=C1N=CN=N1 MDTUWBLTRPRXBX-UHFFFAOYSA-N 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41788902P | 2002-10-11 | 2002-10-11 | |
| PCT/US2003/031413 WO2004032840A2 (en) | 2002-10-11 | 2003-10-02 | Compounds, compositions, and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20052267L true NO20052267L (no) | 2005-05-31 |
Family
ID=32094113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052267A NO20052267L (no) | 2002-10-11 | 2005-05-10 | Forbindelser, Preparater og Metoder |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7476743B2 (https=) |
| EP (1) | EP1558588A4 (https=) |
| JP (1) | JP2006502219A (https=) |
| KR (1) | KR20050075356A (https=) |
| CN (1) | CN1726198A (https=) |
| AR (1) | AR044193A1 (https=) |
| AU (1) | AU2003282665A1 (https=) |
| BR (1) | BR0315247A (https=) |
| CA (1) | CA2501938A1 (https=) |
| IL (1) | IL167936A0 (https=) |
| IS (1) | IS7798A (https=) |
| MX (1) | MXPA05003830A (https=) |
| NO (1) | NO20052267L (https=) |
| NZ (1) | NZ539643A (https=) |
| PL (1) | PL375889A1 (https=) |
| RU (1) | RU2005114491A (https=) |
| TW (1) | TW200418818A (https=) |
| WO (1) | WO2004032840A2 (https=) |
| ZA (1) | ZA200503733B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0510929A (pt) * | 2004-06-18 | 2007-07-17 | Chiron Corp | derivados de n-(1-(1-benzil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil) benzamida e compostos relacionados como inibidores de proteìna de eixo de kinesin (ksp) para o tratamento de cáncer |
| EP1781674A1 (en) | 2004-08-18 | 2007-05-09 | AstraZeneca AB | Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer |
| DE102006023337A1 (de) * | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | Triazolderivate II |
| JP5343363B2 (ja) * | 2008-01-31 | 2013-11-13 | アイシン精機株式会社 | シートクッション調整装置 |
| CN101643451B (zh) * | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法 |
| EA201201404A1 (ru) | 2010-04-15 | 2013-04-30 | Новартис Аг | Триазолы как ингибиторы кбв (кинезин-белок веретена) |
| WO2012095691A1 (en) * | 2011-01-15 | 2012-07-19 | Jubilant Life Sciences Ltd. | An improved process for producing aminopyridines |
| EP2822931B1 (en) | 2012-03-09 | 2017-05-03 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| SG11201504622PA (en) | 2012-12-20 | 2015-07-30 | Inception 2 Inc | Triazolone compounds and uses thereof |
| CN105579440A (zh) | 2013-09-06 | 2016-05-11 | 因森普深2公司 | 三唑酮化合物及其应用 |
| JP6971858B2 (ja) | 2015-06-22 | 2021-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ） |
| TW201722958A (zh) * | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產（第二）有限公司 | 化學化合物 |
| CN110312534B (zh) | 2016-12-21 | 2023-04-04 | 拜耳制药股份公司 | 具有酶促可裂解基团的抗体-药物-缀合物(adc) |
| US20250215039A1 (en) * | 2022-03-30 | 2025-07-03 | Primefour Therapeutics, Inc. | Nucleosides for treating cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE793532A (fr) * | 1971-12-29 | 1973-06-29 | Upjohn Co | Nouvelles 1,2,4-triazol-3-ones et leur preparation |
| US3748339A (en) * | 1972-05-05 | 1973-07-24 | Upjohn Co | 2-(3-(1-(dimethylamino)alkyl)-1,5-dihydro-5-oxo - 1 - substituted-4h-1,2,4-triazol-4-yl)benzophenone and process |
| IT1068010B (it) * | 1976-11-17 | 1985-03-21 | Montedison Spa | Nuovi esteri fosforici derivati dall' 1-2-4 triazolo ad azione insetticida,nematocida e acaricida e loro preparazione |
| NL7712430A (nl) * | 1976-11-17 | 1978-05-19 | Montedison Spa | Nieuwe fosforzuuresters, afgeleid van 1.2.4- -triazool, met een insecticide, nematocide en acaricide werking en werkwijze ter bereiding daarvan. |
| US4487773A (en) * | 1981-03-16 | 1984-12-11 | Mead Johnson & Company | 1,2,4-Triazol-3-one antidepressants |
| US5250558A (en) * | 1992-01-28 | 1993-10-05 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis |
| GB9211193D0 (en) | 1992-05-27 | 1992-07-08 | Merck Sharp & Dohme | Therapeutic agents |
| IL106142A (en) * | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
| AU722883B2 (en) * | 1995-10-18 | 2000-08-10 | Merck & Co., Inc. | Cyclopentyl tachykinin receptor antagonists |
| JP2002234874A (ja) * | 2000-09-26 | 2002-08-23 | Tanabe Seiyaku Co Ltd | ５−フェニルベンジルアミン誘導体、その製法及びその合成中間体 |
| US6727244B2 (en) * | 2000-10-26 | 2004-04-27 | Merck & Co., Inc. | Mammalian metabolites of a tachykinin receptor antagonist |
| EP1515724B1 (en) * | 2002-06-14 | 2009-10-21 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
-
2003
- 2003-10-02 BR BR0315247-2A patent/BR0315247A/pt not_active IP Right Cessation
- 2003-10-02 EP EP03774548A patent/EP1558588A4/en not_active Withdrawn
- 2003-10-02 RU RU2005114491/04A patent/RU2005114491A/ru not_active Application Discontinuation
- 2003-10-02 AU AU2003282665A patent/AU2003282665A1/en not_active Abandoned
- 2003-10-02 MX MXPA05003830A patent/MXPA05003830A/es unknown
- 2003-10-02 CN CNA200380105737XA patent/CN1726198A/zh active Pending
- 2003-10-02 NZ NZ539643A patent/NZ539643A/en unknown
- 2003-10-02 KR KR1020057006260A patent/KR20050075356A/ko not_active Withdrawn
- 2003-10-02 CA CA002501938A patent/CA2501938A1/en not_active Abandoned
- 2003-10-02 PL PL03375889A patent/PL375889A1/xx unknown
- 2003-10-02 WO PCT/US2003/031413 patent/WO2004032840A2/en not_active Ceased
- 2003-10-02 US US10/529,634 patent/US7476743B2/en not_active Expired - Fee Related
- 2003-10-02 JP JP2004543136A patent/JP2006502219A/ja active Pending
- 2003-10-09 AR ARP030103684A patent/AR044193A1/es unknown
- 2003-10-09 TW TW092128029A patent/TW200418818A/zh unknown
-
2005
- 2005-04-10 IL IL167936A patent/IL167936A0/en unknown
- 2005-04-11 IS IS7798A patent/IS7798A/is unknown
- 2005-05-10 NO NO20052267A patent/NO20052267L/no not_active Application Discontinuation
- 2005-05-10 ZA ZA200503733A patent/ZA200503733B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004032840A3 (en) | 2004-10-14 |
| IL167936A0 (en) | 2009-02-11 |
| EP1558588A2 (en) | 2005-08-03 |
| US20060189671A1 (en) | 2006-08-24 |
| RU2005114491A (ru) | 2006-02-10 |
| IS7798A (is) | 2005-04-11 |
| PL375889A1 (en) | 2005-12-12 |
| AU2003282665A1 (en) | 2004-05-04 |
| CN1726198A (zh) | 2006-01-25 |
| MXPA05003830A (es) | 2005-06-23 |
| TW200418818A (en) | 2004-10-01 |
| KR20050075356A (ko) | 2005-07-20 |
| CA2501938A1 (en) | 2004-04-22 |
| ZA200503733B (en) | 2006-02-22 |
| NZ539643A (en) | 2006-11-30 |
| EP1558588A4 (en) | 2006-11-02 |
| US7476743B2 (en) | 2009-01-13 |
| BR0315247A (pt) | 2005-08-30 |
| AR044193A1 (es) | 2005-09-07 |
| JP2006502219A (ja) | 2006-01-19 |
| WO2004032840A2 (en) | 2004-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20045043L (no) | Pyrimidinonforbindelser, sammensetninger og fremgangsmater | |
| WO2004018058A3 (en) | Compounds, compositions, and methods | |
| MY140169A (en) | Compounds, compositions, and methods | |
| WO2004009036A3 (en) | Compounds compositions and methods | |
| MXPA06012796A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| WO2004034972A3 (en) | Compounds, compositions, and methods | |
| MY151032A (en) | Treatment of tnf? related disorders | |
| WO2004064741A3 (en) | Compounds, compositions, and methods | |
| NO20021907L (no) | Metoder og blandinger som anvender kinazolinoner | |
| NO20026172L (no) | Fremgangsmåter og blandinger ved anvendelse av kinazolinoner | |
| DK1305286T3 (da) | Cyclopentanoindoler, præparater indeholdende sådanne forbindelser og fremgangsmåder til behandling | |
| NO20003600D0 (no) | Kaliumkanal inhibitorer | |
| WO2003074550A3 (en) | Pin1-modulating compounds and methods of use thereof | |
| NO20052267L (no) | Forbindelser, Preparater og Metoder | |
| AU2003252025A1 (en) | Compounds, compositions, and methods | |
| NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
| WO2005046588A3 (en) | Compounds, compositions, and methods | |
| WO2005042697A3 (en) | Compounds, compositions and methods | |
| WO2004032879A3 (en) | Compounds, compositions, and methods | |
| WO2004100873A3 (en) | Compounds, compositions, and methods | |
| WO2004024086A3 (en) | Compounds, compositions and methods | |
| WO2005062847A3 (en) | Compounds, compositions and methods | |
| NO20016380L (no) | Fremgangsmåte for å forhindre tumorvekst | |
| WO2005041888A3 (en) | Pyrimidin-4-one compounds, compositions and methods | |
| WO2004103282A3 (en) | Compounds, compositions and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |